FLOMAX RELIEF MR

Male 45 to 75 years. One capsule daily, to be taken after the same meal each day. The capsule should be swallowed whole and should not be crunched or chewed as this will interfere with the modified release of the active ingredient.

3%) headache syncope Eye disorders Vision blurred* Visual impairment * Cardiac disorders palpitations Vascular disorders orthostatic hypotensio n Respiratory, thoracic and mediastinal disorders rhinitis Epistaxis* Gastro- intestinal disorders constipatio n, diarrhoea, nausea, vomiting Dry Mouth* Skin and subcutaneous tissue disorders rash, pruritus, urticaria angioedema Stevens- Johnson syndrome Erythema multiforme * Dermatitis exfoliative* Reproductive systems and breast disorders ejaculation disorders, including retrograde ejaculation and ejaculation failure priapism General disorders and administratio n site disorders asthenia *observed post-marketing.

As with other alpha-blockers, drowsiness or oedema can occur. 4).

Post-marketing experience:

In addition to the adverse events listed above, atrial fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association with tamsulosin use. Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of tamsulosin in their causation cannot be estimated from the available data.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

As with other alpha1 blockers, a reduction in blood pressure can occur in individual cases during treatment with Flomax Relief, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness) the patient should sit or lie down until the symptoms have disappeared.

The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract and glaucoma surgery in some patients on or previously treated with tamsulosin hydrochloride. IFIS may increase the risk of eye complications during and after the operation.

Discontinuing tamsulosin hydrochloride 1 – 2 weeks prior to cataract or glaucoma surgery is anecdotally considered helpful, but the benefit of treatment discontinuation has not been established. IFIS has also been reported in patients who had discontinued tamsulosin for a longer period prior to the surgery.

The initiation of therapy with tamsulosin hydrochloride in patients for whom cataract or glaucoma surgery is scheduled is not recommended. During pre-operative assessment, surgeons and ophthalmic teams should consider whether patients scheduled for cataract or glaucoma surgery are being or have been treated with tamsulosin in order to ensure that appropriate measures will be in place to manage the IFIS during surgery.

g. ketoconazole) in patients with poor metaboliser CYP2D6 phenotype. g. g. 5). g. doxazosin, indoramin, prazosin, terazosin, verapamil) without first consulting a doctor. Flomax Relief should not be given to a man who experiences postural hypotension.

Flomax Relief should not be supplied to any man with heart, renal, or liver disease, uncontrolled diabetes, urinary incontinence, or to a man who has had prostate surgery. Flomax Relief should not be supplied to a man whose symptoms are of less than 3 months duration.

Flomax Relief should not be given to any man who reports dysuria, haematuria, or cloudy urine, in the past 3 months, or who is suffering from a fever that might be related to a urinary tract infection. Flomax Relief should not be used in those planning to have eye surgery for cataract or glaucoma, or who have recently experienced blurred or cloudy vision that has not been examined by a GP or Optician.

Hypersensitivity to tamsulosin hydrochloride, including drug-induced angioedema, or any other component of the product; a history of orthostatic hypotension; severe hepatic insufficiency.